The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Serevent Diskus
(United States) [Available]Synonyms :
salmeterol
Class :
Drugs for asthma and COPD & Bronchodilators (Beta2-agonists/ Adrenergic agonists)
Dosage forms & Strengths:
Adult:
Powder
50mcg/inhalation
Powder
50mcg/inhalation
may increase the hypokalemic effect of thiazide diuretics
may increase the hypokalemic effect of thiazide diuretics
may increase the hypokalemic effect of thiazide diuretics
may increase the hypokalemic effect of thiazide diuretics
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
QTc interval is increased both by lenvatinib and salmeterol
may increase the toxic effect of beta2 agonists
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may enhance the concentration of serum when combined with salmeterol
may enhance the concentration of serum when combined with salmeterol
may enhance the concentration of serum when combined with salmeterol
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
salmeterol: they may enhance the serum concentration of CYP3A Inhibitors
salmeterol: they may enhance the serum concentration of CYP3A Inhibitors
salmeterol: they may enhance the serum concentration of CYP3A Inhibitors
salmeterol: they may enhance the serum concentration of CYP3A Inhibitors
salmeterol: they may enhance the serum concentration of CYP3A Inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may increase the hypokalemic effect of thiazide diuretics
may increase the hypokalemic effect of thiazide diuretics
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
when used together, entrectinib and salmeterol both increase the QTc interval
may increase the tachycardic effect of atomoxetine
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
lisinopril/hydrochlorothiazide
may increase the hypokalemic effect of blood pressure-lowering agents
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
The stimulation of beta-2 adrenoceptors results in bronchodilation, relaxation of the bronchial smooth muscle, and an increase in airflow.
Salmeterol is believed to attach to two beta-2 adrenoceptor sites. It attaches itself to the beta-2 adrenoceptor’s active site.
Salmeterol’s hydrophilic tail attaches to leucine residues in the beta-2 adrenoceptor’s exo-site nearly irreversibly that allows it to remain in the active site.
Frequency defined:
>10%:
Nasopharyngitis (11%)
1%-10%
Skin rash (2%)
Urinary tract infection (3%)
Back pain (4%)
Arthralgia (2%)
Bronchitis (5%)
<1%:
Angina pectoris
Cardiac arrhythmia
Cough
Dermatitis
Fatigue
Variable blood pressure
Restlessness
Nervousness
Data from a major placebo-controlled U.S. trial indicated that participants receiving salmeterol alone experienced an increase in asthma-related deaths, indicating that LABA as ICS increase the risk of asthma-related death.
When treating asthma, it is not recommended to use a medication as monotherapy without a concurrent ICS. It should be used as supplemental treatment for patients whose asthma is already under control on an ICS.
Patients whose asthma is adequately controlled on low- or medium-dose ICS should not use a medication.
A fixed-dose combination product that contains both an ICS and a LABA should typically be used for pediatric and adolescent asthma patients who need to add a LABA to an ICS to ensure adherence to both medications.
Contraindication:
Hypersensitivity
Primary treatment for acute episodes of asthma or COPD requiring extensive interventions
Caution:
Cardiovascular disorders
Diabetes mellitus and ketoacidosis
Hypokalemia
Hepatic impairment
Seizure disorders
Pregnancy consideration: The use of salmeterol is preferred for the management of asthma in pregnant patients.
Lactation: Excretion of salmeterol in breast milk is not known.
Pregnancy category:
Salmeterol is a long-acting agonist that binds to the beta-2 adrenergic receptor’s exo and active sites.
The duration of action of salmeterol is longer than other beta-2 agonists.
The lipophilic drug delivers a longer-lasting drug depot to the smooth muscle cells by diffusing into their lipid bilayer.
For asthma attacks, salmeterol is not a cure. Only use inhalation medications that respond quickly to prevent an attack.
For asthma, salmeterol inhalation must be used in conjunction with an inhaled steroid medication to provide long-term asthma control.
It is not advisable to abruptly stop using steroid medications if you also take them.
Patient information leaflet
Generic Name: salmeterol
Why do we use salmeterol?
Salmeterol is used in the treatment of asthma with an inhaled corticosteroid and in prevention of exercise induced bronchospasm.
It is also used in the maintenance of airflow obstruction and prevention of exacerbations of chronic obstructive pulmonary disease.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
